Patents by Inventor Madeline M. Butler

Madeline M. Butler has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Antisense oligonucleotide modulation of tumor necrosis factor-(&agr;) (TNF-&agr;) expression
    Patent number: 6228642
    Abstract: Compositions and methods are provided for inhibiting the expression of human tumor necrosis factor-&agr; (TNF-&agr;). Antisense oligonucleotides targeted to nucleic acids encoding TNF-&agr; are preferred. Methods of using these oligonucleotides for inhibition of TNF-&agr; expression and for treatment of diseases, particularly inflammatory and autoimmune diseases, associated with overexpression of TNF-&agr; are provided.
    Type: Grant
    Filed: May 18, 1999
    Date of Patent: May 8, 2001
    Assignee: Isis Pharmaceuticals, Inc.
    Inventors: Brenda F. Baker, C. Frank Bennett, Madeline M. Butler, William R. Shanahan, Jr.
  • Antisense modulation of pepck-cytosolic expression
    Patent number: 6187545
    Abstract: Antisense compounds, compositions and methods are provided for modulating the expression of PEPCK-cytosolic. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding PEPCK-cytosolic. Methods of using these compounds for modulation of PEPCK-cytosolic expression and for treatment of diseases associated with expression of PEPCK-cytosolic are provided.
    Type: Grant
    Filed: January 21, 2000
    Date of Patent: February 13, 2001
    Assignee: Isis Pharmaceuticals Inc.
    Inventors: Robert McKay, Madeline M. Butler, Jacqueline Wyatt, Lex M. Cowsert
  • Antisense oligonucleotide modulation of tumor necrosis factor-.alpha. (TNF-.alpha.) expression
    Patent number: 6080580
    Abstract: Compositions and methods are provided for inhibiting the expression of human tumor necrosis factor-.alpha. (TNF-.alpha.). Antisense oligonucleotides targeted to nucleic acids encoding TNF-.alpha. are preferred. Methods of using these oligonucleotides for inhibition of TNF-.alpha. expression and for treatment of diseases, particularly inflammatory and autoimmune diseases, associated with overexpression of TNF-.alpha. are provided.
    Type: Grant
    Filed: October 5, 1998
    Date of Patent: June 27, 2000
    Assignee: Isis Pharmaceuticals Inc.
    Inventors: Brenda F. Baker, C. Frank Bennett, Madeline M. Butler, William R. Shanahan, Jr.
  • Antisense inhibition of PEPCK-mitochondrial expression
    Patent number: 6030837
    Abstract: Antisense compounds, compositions and methods are provided for modulating the expression of PEPCK-mitochondrial. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding PEPCK-mitochondrial. Methods of using these compounds for modulation of PEPCK-mitochondrial expression and for treatment of diseases associated with expression of PEPCK-mitochondrial are provided.
    Type: Grant
    Filed: August 3, 1999
    Date of Patent: February 29, 2000
    Assignee: Isis Pharmaceuticals Inc.
    Inventors: Robert McKay, Madeline M. Butler, Lex M. Cowsert